Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

  • days left to enroll
  • participants needed
  • sponsor
    University of North Carolina, Chapel Hill
Updated on 26 January 2021


Individuals with kidney failure receiving maintenance hemodialysis (HD) have high mortality rates, driven largely by cardiovascular causes. Volume-related factors are critical, modifiable contributors to cardiovascular complications. Reversing volume overload has been shown to improve blood pressure and cardiac remodeling. Use of loop diuretics may represent a pragmatic, low-cost, and low-burden strategy to improve outcomes in people receiving HD. Lack of data on optimal furosemide dosing, safety, and acceptability are barriers to expanded use. This study investigates whether oral furosemide is safe and effective at increasing urine volume in HD patients.

Condition Chronic Kidney Disease Requiring Chronic Dialysis
Treatment Furosemide (loop diuretic) Tablets
Clinical Study IdentifierNCT04622709
SponsorUniversity of North Carolina, Chapel Hill
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Patient self-report of at least 1 cup urine/24-hours
Age 18 years
Receipt of thrice weekly in-center HD at a participating clinic (UNC-associated Carolina Dialysis- Carrboro, Siler City, Pittsboro, Sanford, and Lee County)
days receiving in-center HD
Willingness to take study medication and undergo study testing
Ability to provide informed consent

Exclusion Criteria

Known allergy to loop diuretic
History of poor adherence to HD or medical regimen per nephrologist
>1 hospitalization in prior 30-days
Frequent hypotension (systolic BP <80 mmHg at >30% of HD treatments in prior 30-days)
Cirrhosis per nephrologist
Hearing disorder per nephrologist
Serum potassium <3.5 mEq/L, magnesium <1 mg/dL, or corrected calcium <8 mg/dL in prior 30-days
Taking a non-loop diuretic (e.g. spironolactone, eplerenone, ethacrynic acid, thiazides)
Taking an aminoglycoside, cisplatin, methotrexate, cyclosporine, adrenocorticotropic hormone (ACTH), lithium, phenytoin, or oral/intravenous steroid
Natural licorice consumption
Prisoners, patients with significant mental illness
Pregnant patients and nursing mothers
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note